Colorectal cancer screening lacks evidence of benefit
Paul Moayyedi, BSc, MB ChB, PhD, MPH, FRCP, FRCPC
AstraZeneca/Richard Hunt Chair of Gastroenterology, Head, Division of Gastroenterology, McMaster University, Hamilton, Ontario, Canada
Address: Paul Moayyedi, Department of Medicine, Division of Gastroenterology, McMaster University Medical Centre, 1200 Main Street West, HSC 4W8B, Hamilton, Ontario L8N 3Z5, Canada; e-mail: email@example.com
Dr. Moayyedi has disclosed that he has received honoraria and consulting fees from the AstraZeneca and Janssen-Ortho corporations, and that AstraZeneca partly funds his endowed chair through an unrestricted donation.
ABSTRACTAlthough some studies indicate that screening with fecal occult blood testing or colonoscopy prevents deaths from colorectal cancer, the benefits may be offset by more deaths from other causes. Whether this phenomenon is due to anxiety, test bias, or merely chance, more evidence is needed; widespread screening in the general population is premature.